DRG Epidemiology's coverage of thyroid cancer comprises epidemiological estimates of key patient populations across the emerging pharmaceutical markets (Brazil, China, Mexico, Russia, South Korea, Turkey). We report both the incidence and prevalence of thyroid cancer for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the developed world.

DRG Epidemiology's thyroid cancer forecast will answer the following questions:

How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with thyroid cancer per year?

In developing countries, what impact will economic growth and development have on the number of people diagnosed with thyroid cancer per year?

How will improvements in survival change the number of people living with a diagnosis of thyroid cancer?

How will decreasing recurrence risk change the number of people diagnosed with thyroid cancer per year?

How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of thyroid cancer over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.

DRG Epidemiology provides at least ten years of forecast data for the following thyroid cancer patient populations:

  • Diagnosed Follicular Incident Cases
  • Diagnosed Papillary Incident Cases
  • Diagnosed Medullary Incident Cases
  • Diagnosed Anaplastic Incident Cases
  • Diagnosed Follicular Incident Cases – Stage at Diagnosis
  • Diagnosed Papillary Incident Cases – Stage at Diagnosis
  • Diagnosed Medullary Incident Cases – Stage at Diagnosis
  • Diagnosed Anaplastic Incident Cases – Stage at Diagnosis
  • Prevalent Follicular Cases (by remission status)
  • Prevalent Papillary Cases (by remission status)
  • Prevalent Medullary Cases (by remission status)
  • Prevalent Anaplastic Cases (by remission status)
  • Locally Advanced, Unresectable, RAI-refractory Differentiated Thyroid Cancer - Drug-Treatable Population
  • Metastatic, Unresectable, RAI-Refractory Differentiated Thyroid Carcinoma - Drug-Treatable Population
  • Metastatic, Unresectable, Symptomatic and/or Progressive Medullary Thyroid Cancer – Drug-Treatable Population
  • Anaplastic Thyroid Cancer - Drug-Treatable Population

… and many more (details available on request).

Note: coverage may vary by country and region.

Table of contents

  • Thyroid Carcinoma - Epidemiology - Emerging Markets
    • Introduction
      • Key Findings
        • Overview
          • Incidence of Thyroid Cancer per 100,000 per Year Among People of All Ages in 2018 and 2038
          • Patient-Flow Diagram for Thyroid Cancer 2018
          • Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Thyroid Cancer over the Next Ten Years
          • Analysis of Diagnosed Incident Cases of Thyroid Cancer Across the Countries Under Study in 2018 by Histology
      • Epidemiology Data
      • Methods
        • Diagnosed Incident Cases
        • Stage at Diagnosis
        • Recurrent Incident Cases
        • Diagnosed Prevalent Cases
        • Drug-Treatable Populations
        • Lifetime DALYs Gained
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Thyroid Cancer
          • Studies Excluded from the Analysis of Thyroid Cancer
        • Risk/Protective Factors
          • Risk/Protective Factors for Thyroid Cancer
        • Bibliography

    Author(s): Oliver Blandy; Nishant Kumar, MPH

    Oliver Blandy, BSc PGCE MSc, joined Decision Resources Group (DRG) as an Associate Epidemiologist in 2017. He focuses on the epidemiology of cancer.

    Oliver holds an MSc from the University of Bristol where he specialized in Nutrition, Physical Activity and Public Health. He also holds a BSc in Chemistry and has a Post Graduate Certificate in Education (PGCE), both from the University of Bristol and taught general science and Advanced Chemistry in high school for two years.

    Before joining the team at DRG, Oliver worked as a Research Assistant for Imperial College London where he was the lead for several studies within an NIRH funded research group that investigated healthcare associated infections and antimicrobial resistance.

    Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects.

    His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.